[go: up one dir, main page]

AU2001249389A1 - Modified blood clotting factors and methods of use - Google Patents

Modified blood clotting factors and methods of use

Info

Publication number
AU2001249389A1
AU2001249389A1 AU2001249389A AU4938901A AU2001249389A1 AU 2001249389 A1 AU2001249389 A1 AU 2001249389A1 AU 2001249389 A AU2001249389 A AU 2001249389A AU 4938901 A AU4938901 A AU 4938901A AU 2001249389 A1 AU2001249389 A1 AU 2001249389A1
Authority
AU
Australia
Prior art keywords
methods
blood clotting
clotting factors
modified blood
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249389A
Inventor
Rodney M. Camire
Katherine A. High
Paris Margaritis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2001249389A1 publication Critical patent/AU2001249389A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001249389A 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use Abandoned AU2001249389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19133100P 2000-03-22 2000-03-22
US60191331 2000-03-22
PCT/US2001/009355 WO2001070763A1 (en) 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use

Publications (1)

Publication Number Publication Date
AU2001249389A1 true AU2001249389A1 (en) 2001-10-03

Family

ID=22705051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249389A Abandoned AU2001249389A1 (en) 2000-03-22 2001-03-22 Modified blood clotting factors and methods of use

Country Status (3)

Country Link
US (3) US20040102388A1 (en)
AU (1) AU2001249389A1 (en)
WO (1) WO2001070763A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615537B2 (en) * 2000-10-25 2009-11-10 Genzyme Corporation Methods for treating blood coagulation disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (en) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド Construction and method for enhanced expression of recombinant polypeptides from a single vector using peptide cleavage sites
US8211874B2 (en) * 2005-06-03 2012-07-03 Galderma Laboratories Inc. Inhibition of thrombin generation
MX2008006313A (en) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Reactive dyestuffs, method for the production thereof, and use of the same.
CA2573472A1 (en) * 2006-01-23 2007-07-23 Tyco Healthcare Group Lp Biodegradable hemostatic compositions
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
WO2008022151A1 (en) * 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
CA2737094C (en) 2008-09-15 2018-02-20 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
IN2012DN06629A (en) * 2010-01-28 2015-10-23 Philadelphia Children Hospital
PT2591006T (en) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
MX2015008813A (en) 2013-01-31 2016-03-31 Pfizer Compositions and methods for counteracting factor xa inhibition.
RU2648144C2 (en) 2013-09-24 2018-03-22 Пфайзер Инк. COMPOSITIONS COMPRISING HETEROGENEOUS POPULATIONS OF RECOMBINANT HUMAN CLOTTING FACTOR Xa PROTEINS
KR102417915B1 (en) 2014-03-21 2022-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Genome editing without nucleases
WO2016028872A2 (en) 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
FR3035120B1 (en) * 2015-04-15 2020-02-07 Arcadophta IMMOBILIZED PLASMINOGENASE COMPOSITION, PREPARATION METHOD, USE AND DEVICE COMPRISING SUCH COMPOSITION
BR102015012334A2 (en) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp production process of blood coagulation factor vii and blood coagulation factor vii
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
DK3817775T3 (en) * 2018-07-04 2024-09-16 Vaxcyte Inc Improvements in immunogenic conjugates
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
WO2023171719A1 (en) * 2022-03-08 2023-09-14 学校法人自治医科大学 Sequence of activated protein c

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562421B1 (en) * 1984-04-09 1989-02-17 Sandoz Sa IMPROVEMENTS ON INTERLEUKIN THERAPY
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ES2039203T3 (en) * 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. COMPOSITION OF LIPOSOMES.
JP2666345B2 (en) * 1987-04-16 1997-10-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
JPH04503306A (en) * 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション Herpes simplex virus type 1 expression vector
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE69131292T2 (en) * 1990-01-29 1999-09-30 Zymogenetics, Inc. ANTICOAGULATING PROTEINS
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
AU664976B2 (en) * 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
WO1993019660A1 (en) * 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
CA2143125C (en) * 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5674703A (en) * 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
AU684524B2 (en) * 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
AU7353494A (en) * 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
CA2117668C (en) * 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant DNA virus and method for producing the same
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695977A (en) * 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
WO1998024479A1 (en) * 1996-12-02 1998-06-11 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AT405516B (en) * 1997-02-27 1999-09-27 Immuno Ag FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT
AT405517B (en) * 1997-02-27 1999-09-27 Immuno Ag FACTOR X-DELETION MUTANTS AND ANALOGS OF THEM
US20030207402A1 (en) * 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6328958B1 (en) * 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
US6924365B1 (en) * 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US7615537B2 (en) * 2000-10-25 2009-11-10 Genzyme Corporation Methods for treating blood coagulation disorders
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a

Also Published As

Publication number Publication date
WO2001070763A1 (en) 2001-09-27
US20180273607A1 (en) 2018-09-27
US20110126303A1 (en) 2011-05-26
US20040102388A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU2001249389A1 (en) Modified blood clotting factors and methods of use
AU2001270943A1 (en) Surgical instrument and method of using the same
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2002356861A1 (en) Fibrin membrane and methods for its preparation- application to artificial skin
EP1539275A4 (en) Blood aspiration system and methods of use
AU2002215357A1 (en) Puncture resistant branch artery occlusion device and methods of use
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
IL157577A0 (en) Disposable underpants and method of providing the same
AU2001255662A1 (en) Miniaturized surgical forceps and methods of making the same
AU2002314466A1 (en) Withasol and methods of use
AU2001259449A1 (en) Whole blood separator apparatus and method of use
AU2001251358A1 (en) Prion-binding ligands and methods of using same
AU2002320147A1 (en) Microdialysis probes and methods of use
AU3622600A (en) Metalloproteinases and methods of use therefor
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001244461A1 (en) Venous line catheter and method of operating the same
AU2002312315A1 (en) Microfabricated surgical devices and methods of making the same
AU2001251489A1 (en) Assembly for extracorporeal blood handling and method of use
AU2002366343A1 (en) Methods and systems for making disposable absorbent article having graphics
AU2001277202A1 (en) Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2002216092A1 (en) Method and device for determining the topology of biological tissue
AU3501700A (en) Human endokine alpha and methods of use